Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELL | P14151 | 2/20 | 0.47 |
| ▸ | SELP | P16109 | 2/20 | 0.47 |
| ▸ | SELE | P16581 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 5/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA6 | P23280 | 2/20 | 0.41 |
| ▸ | FUT7 | Q11130 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | FUT4 | P22083 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20239110 | 0.80 | CYP3A4 (0.43) | TDP1ALDH1A1HPGDHSD17B10CA1 | |
| SCHEMBL561678 | 0.76 | PTGS2 (0.50) | LMNATDP1ALDH1A1KDM4EHPGD | |
| SCHEMBL1521865 | 0.73 | ESR1 (0.37) | CA1CA6CA12CA3CA5A | |
| SCHEMBL7296012 | 0.71 | LMNA (0.48) | SELLSELPSELELMNATDP1 | |
| SCHEMBL15769323 | 0.71 | GPR35 (0.62) | TDP1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL25183526 | 0.69 | SELL (0.53) | SELLSELPSELELMNATDP1 | |
| SCHEMBL67497 | 0.69 | BACE1 (0.54) | SELLSELPSELELMNATDP1 | |
| SCHEMBL8614617 | 0.67 | — | — | |
| SCHEMBL3293550 | 0.67 | CA1 (0.58) | SELLSELPSELELMNAALDH1A1 | |
| SCHEMBL188272 | 0.67 | TDP1 (0.58) | TDP1ALDH1A1KDM4EHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 271 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4178959-A1 | NITROGEN HETEROCYCLIC CYTOKININ DERIVATIVES, COMPOSITIONS CONTAINING THESE DERIVATIVES AND USE THEREOF | Univerzita Palackého v Olomouci (CZ) | 2023-05-17 | — | — | EP | claimed |
| US-11643413-B2 | 9-(2-oxacycloalkyl)-9H-purine-2,6-diamine derivatives and their use for the treatment of skin disorders | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2023-05-09 | — | — | US | claimed |
| EP-3615535-B1 | 9-(2-OXACYCLOALKYL)-9H-PURINE-2,6-DIAMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS | UNIV PALACKEHO (CZ) | 2022-06-15 | — | — | EP | claimed |
| WO-2022012702-A1 | NITROGEN HETEROCYCLIC CYTOKININ DERIVATIVES, COMPOSITIONS CONTAINING THESE DERIVATIVES AND USE THEREOF | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2022-01-20 | — | — | WO | claimed |
| US-20200157105-A1 | 9-(2-OXACYCLOALKYL)-9H-PURINE-2,6-DIAMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2020-05-21 | — | — | US | claimed |
| EP-3615535-A1 | 9-(2-OXACYCLOALKYL)-9H-PURINE-2,6-DIAMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS | Univerzita Palackého v Olomouci (CZ) | 2020-03-04 | — | — | EP | claimed |
| WO-2018196893-A1 | 9-(2-OXACYCLOALKYL)-9H-PURINE-2,6-DIAMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2018-11-01 | — | — | WO | claimed |
| CN-102659837-B | Solanesol phosphamide derivatives and their preparation method and use | UNIV SHIJIAZHUANG | 2015-07-15 | — | — | CN | claimed |
| EP-0238061-B1 | CEPHALOSPORIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND ANTIBACTERIAL AGENTS | Banyu Pharmaceutical Co., Ltd. (JP) | 1992-10-21 | — | — | EP | claimed |
| US-4880797-A | THIAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-11-14 | — | — | US | claimed |
| EP-0238061-A2 | Cephalosporin derivatives, processes for their preparation and antibacterial agents | Banyu Pharmaceutical Co., Ltd. (JP) | 1987-09-23 | — | — | EP | claimed |
| EP-4373526-A1 | COMPOSITIONS AND USES OF TRIGLYCERIDE MIMETICS TO TARGET SELECTIVELY MICROBIAL LIPASE | Excella Bioscientific Ltd (IL) | 2024-05-29 | — | — | EP | disclosed |
| WO-2024100140-A1 | METHOD FOR PRODUCING EPIGALLOCATECHIN GALLATE MONOGLUCOSIDE | GIVAUDAN SA (CH) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024083721-A1 | A METHOD OF PROVIDING HIGH SPF TO A TOPICAL SURFACE OF A BODY | UNILEVER IP HOLDINGS B.V. (NL) | 2024-04-25 | — | — | WO | disclosed |
| CN-113226476-B | Novel method and cosmetic composition for luster and blurriness | 联合利华知识产权控股有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-4880797-A | THIAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-11-14 | — | — | US | disclosed |
| US-4760064-A | Cardiotonic agent | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-07-26 | — | — | US | disclosed |
| EP-0238061-A2 | Cephalosporin derivatives, processes for their preparation and antibacterial agents | Banyu Pharmaceutical Co., Ltd. (JP) | 1987-09-23 | — | — | EP | disclosed |
| EP-0187322-A1 | Carbostyril compounds, compositions containing same and processes for preparing same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-07-16 | — | — | EP | disclosed |
| US-4415572-A | CARDIOTONIC AND INOTROPIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1983-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157105-A1 | 9-(2-OXACYCLOALKYL)-9H-PURINE-2,6-DIAMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS | ADORA2A, UNG, P2RY6 | SELL 3484/4885SELP 2820/4885SELE 3184/4885 |
| US-11643413-B2 | 9-(2-oxacycloalkyl)-9H-purine-2,6-diamine derivatives and their use for the treatment of skin disorders | ADORA2A, UNG, P2RY6 | SELL 3484/4885SELP 2820/4885SELE 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.